Can a special PET scan spot returning prostate cancer after targeted therapy?
NCT ID NCT07011342
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This study is testing whether a PSMA-PET scan using a radioactive tracer called 18F-rhPSMA-7.3 can accurately detect prostate cancer that has come back after focal gland treatment. About 70 men who had focal therapy for intermediate-risk prostate cancer will receive the scan, and the results will be compared to standard biopsy findings one year after treatment. The goal is to see if this imaging method can reliably identify recurrence without relying solely on biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-rhPSMA-7.3 (a radioactive tracer used in PET scans)
What this could lead to
If successful, this scan could become a reliable way to detect prostate cancer recurrence after focal therapy, potentially reducing the need for invasive biopsies.
What could go wrong
This is an early-stage study with only 70 participants, so results may not apply to all patients. The scan may miss some recurrences or show false positives.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.